Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with tumor thrombosis of the portal vein tumor thrombosis

Table 2 Factors associated with cumulative survival of pa-tients by univariate analysis (log-rank test)

	P value*
Gender (male/female)	0.950
Age (younger than 60 yrs/60 yrs and older)	0.948
HBV/HCV	0.825
Child-Pugh’s stage (A/B/C)	0.001
Previous treatment (yes/no)	0.753
Serum AFP (<1000 ng.ml-1/ ≥ 1000 ng.ml-1)	0.994
Tumor location (unilobe/bilobe)	0.938
Tumor type (nodular/massive/diffuse)	0.541
Maximum tumor size (<5 cm/ ≥ 5 cm)	0.761
Tumor extent (E1/E2/E3/E4)ac	0.429
Grade of portal vein invasion (Vp1/Vp2/Vp3)bd	0.309
Completion of protocol (yes/no)	0.155
Therapeutic response (CR/ PR/ ST/PD)	< 0.001

HBV: hepatitis B virus; HCV: hepatitis C virus; AFP: α- fetoprotein; Vp: portal vein tumor thrombosis; CR: complete response; PR: partial response; ST: stable disease; PD: progres-sive disease.

^acTumor extent. Tumor replacement of liver parenchyma: E1, < 20%; E2, 20%-40%; E3, 40%-60%; E4, > 60%.

^bdPortal vein invasion. Vp1: in a third or more of the periph-eral branch; Vp2: in the second branch; Vp3: in the first branch or trunk.